Matches in Wikidata for { <http://www.wikidata.org/entity/Q91720452> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q91720452 description "article scientifique publié en 2020" @default.
- Q91720452 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q91720452 description "scientific article published on 01 April 2020" @default.
- Q91720452 description "wetenschappelijk artikel" @default.
- Q91720452 description "наукова стаття, опублікована 1 квітня 2020" @default.
- Q91720452 name "Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY" @default.
- Q91720452 name "Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY" @default.
- Q91720452 type Item @default.
- Q91720452 label "Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY" @default.
- Q91720452 label "Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY" @default.
- Q91720452 prefLabel "Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY" @default.
- Q91720452 prefLabel "Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY" @default.
- Q91720452 P1433 Q91720452-1992D16D-3E73-4739-936E-626818D19CF5 @default.
- Q91720452 P1476 Q91720452-0A66816D-2A97-4301-9EC5-AB8144FA4030 @default.
- Q91720452 P2093 Q91720452-344B1A0F-D186-42C5-8FDC-4376382DF9E7 @default.
- Q91720452 P2093 Q91720452-98F4CF4E-C042-478B-8E17-125E03F7EF1C @default.
- Q91720452 P2093 Q91720452-CE1DC355-9A03-4D08-9DCA-EEE1308EC016 @default.
- Q91720452 P304 Q91720452-41E504DE-DE70-4764-B473-9ACD6971EA52 @default.
- Q91720452 P31 Q91720452-FDA8D460-2A39-4EDF-8B44-35590FE4B526 @default.
- Q91720452 P31 Q91720452-f4d0f14d-f615-46e1-ac83-296ab730b787 @default.
- Q91720452 P356 Q91720452-373AD971-3F33-4E9B-94FF-19990BED2118 @default.
- Q91720452 P478 Q91720452-5BA4E11D-A2A9-4C96-9DE5-FAF9FB42B1B9 @default.
- Q91720452 P50 Q91720452-A2DE3E27-60D3-4635-B6CE-48E6839FFB37 @default.
- Q91720452 P577 Q91720452-019C0888-148F-4709-B466-B695A7B9C71F @default.
- Q91720452 P698 Q91720452-27F88D82-93C1-4F5C-81A8-A81DB37CE21E @default.
- Q91720452 P356 DOM.13987 @default.
- Q91720452 P698 32267076 @default.
- Q91720452 P1433 Q5270109 @default.
- Q91720452 P1476 "Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY" @default.
- Q91720452 P2093 "Glenn M Chertow" @default.
- Q91720452 P2093 "Kenneth W Mahaffey" @default.
- Q91720452 P2093 "Meg J Jardine" @default.
- Q91720452 P304 "46-54" @default.
- Q91720452 P31 Q13442814 @default.
- Q91720452 P31 Q7318358 @default.
- Q91720452 P356 "10.1111/DOM.13987" @default.
- Q91720452 P478 "22 Suppl 1" @default.
- Q91720452 P50 Q91720447 @default.
- Q91720452 P577 "2020-04-01T00:00:00Z" @default.
- Q91720452 P698 "32267076" @default.